Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 135 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: tiotropium-bromide Clear all
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg, Placebo (for Olodaterol (BI1744)l), Placebo (for Tiotropium)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

NCT00106821
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide Inhalation Powder
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

NCT01662986
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Montgomery, Alabama • Flagstaff, Arizona • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

NCT00144339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
5,993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
95
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

NCT02006732
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

NCT00359788
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Dynamic Hyperinflation and Tiotropium

NCT00569270
View directory record Official record
Conditions
COPD
Interventions
Placebo
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

NCT00274508
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One Year Study in COPD.

NCT00387088
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat, Tiotropium
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
3,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

NCT00772538
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Not listed Phase 1 Interventional

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

NCT01355991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05986591
View directory record Official record
Conditions
COPD
Interventions
Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg, Placebo
Combination Product
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02276222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
83
States / cities
Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00240435
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
14
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

NCT02845752
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Stiolto Respimat, Placebo Respimat
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
45 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

NCT00523991
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Jasper, Alabama • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics

NCT02382510
View directory record Official record
Conditions
Asthma
Interventions
TRN-157, Placebo, Tiotropium
Drug · Other
Lead sponsor
Theron Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Costa Mesa, California • Gold River, California • Reno, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

NCT01899742
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Medford, Oregon • Greenville, South Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

NCT00308191
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate, Tiotropium Bromide
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Sepulveda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01587079
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003, PT001, PT005, Tiotropium inhalation powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
19
States / cities
Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 2, 2026, 9:28 AM EDT